Investor Relations

Latest Financial Results

Q2 2020

Quarter Ended Jun 30, 2020

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA.  Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com.   The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder.  The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.

Investor Contact Information

Company

Trevena, Inc.
955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087
T: (610) 354-8840
ir@trevena.com

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
Managing Director
T: 617-430-7576
daniel@lifesciadvisors.com